×
Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after d...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059985
International Immunopharmacology; Zhao H, Zhang C et. al.

Apr 30th, 2021 - The clinical characteristics and treatment of patients who tested positive for COVID-19 after recovery remained elusive. Effective antiviral therapy is important for tackling these patients. We assessed the efficacy and safety of favipiravir for treating these patients. This is a multicenter, open-label, randomized controlled trial in SARS-CoV-2 RNA re-positive patients. Patients were randomly ...

Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection.
https://doi.org/10.1097/QCO.0000000000000724 10.1371/journal.pone.0241541 10.1093/cid/ciaa1288 10.1038/s41467-020-20053-y 10.1128/mBio.02374-20 10.7554/eLife.57309 10.1177/0022034520918518 10.7759/cureus.7560 10.7554/elife.57149 10.1126/sciimmunol.abd6160 10.3389/fimmu.2020.586984 10.3390/life10120345 10.3389/fmolb.2020.00157
Current Opinion in Infectious Diseases; Fröberg J, Diavatopoulos DA

Apr 26th, 2021 - Despite its crucial role in protection against viral infections, mucosal immunity has been largely understudied in the context of coronavirus disease 2019 (COVID-19). This review outlines the current evidence about the role of mucosal immune responses in the clearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, as well as potential mucosal mechanisms of protection...

Respiratory Viral Shedding in Healthcare Workers Reinfected with SARS-CoV-2, Brazil, 2020.
https://doi.org/10.3201/eid2706.210558
Emerging Infectious Diseases; Amorim MR, Souza WM et. al.

Apr 19th, 2021 - We documented 4 cases of severe acute respiratory syndrome coronavirus 2 reinfection by non-variant of concern strains among healthcare workers in Campinas, Brazil. We isolated infectious particles from nasopharyngeal secretions during both infection episodes. Improved and continued protection measures are necessary to mitigate the risk for reinfection among healthcare workers.

Reinfection of SARS-CoV-2 - analysis of 23 cases from the literature.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054490
Infectious Diseases (London, England); Roberts AT, Piani F et. al.

Apr 14th, 2021 - The duration of immunity after infection from SARS-CoV-2 conferring protection from subsequent COVID-19 episodes is not yet fully understood. We reviewed the literature for cases of documented reinfection. A comprehensive computerized search in PubMed, through 15 December 2020, using the following terms in combination: COVID-19, SARS-CoV-2, reinfection, reactivation, recurrence. To exclude case...

Exploring the potential roles of some rodents in the transmission of the Middle East re...
https://doi.org/10.1002/jmv.27023
Journal of Medical Virology; Hemida MG, Alhammadi M et. al.

Apr 14th, 2021 - Middle East respiratory syndrome coronavirus (MERS-CoV) is one of the recently identified zoonotic coronaviruses. The one-hump camels are believed to play important roles in the evolution and transmission of the virus. The animal-to-animal, as well as the animal-to-human transmission in the context of MERS-CoV infection, were reported. The camels shed the virus in some of their secretions, espe...

Hydroxychloroquine in mild-to-moderate COVID-19: a placebo-controlled double blind trial.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015393
Clinical Microbiology and Infection : the Official Public... Dubée V, Roy PM et. al.

Apr 4th, 2021 - To determine whether hydroxychloroquine decreases the risk of adverse outcome in patients with mild-to-moderate COVID-19 at high risk of worsening. We conducted a multicentre randomized double-blind placebo-controlled trial evaluating hydroxychloroquine in COVID-19 patients with at least one of the following risk factors for worsening: need for supplemental oxygen, age ≥75 years, age between 60...

Clinical characteristics of COVID-19 in neonates and young infants.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009690
European Journal of Pediatrics; Spoulou V, Noni M et. al.

Mar 31st, 2021 - We report the clinical characteristics and management of fourteen neonates and very young infants with COVID-19. Although all presented with mild symptoms and did not require specific treatment, most of them had abnormal laboratory and radiological findings. Ten infants presented with neutropenia and/or monocytosis but none with lymphopenia. Transient hypertriglyceridemia and/or prolonged viral...

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a ran...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009873
Nature Communications; Jagannathan P, Andrews JR et. al.

Mar 31st, 2021 - Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized, single-blind, placebo-controlled trial (NCT04331899) in 120 outpatients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) within 72 hours of diagnosis could shorten the durati...

SARS-CoV-2 infection of the oral cavity and saliva.
https://doi.org/10.1038/s41591-021-01296-8 10.1056/NEJMoa2001017 10.1073/pnas.2009637117 10.1016/S0140-6736(20)30607-3 10.1016/S0140-6736(20)30528-6 10.15585/mmwr.mm6919e6 10.1016/j.cell.2020.05.042 10.1001/jamadermatol.2020.2550 10.1371/journal.ppat.1006798 10.1016/j.cell.2020.05.048 10.3389/fimmu.2021.620124 10.1016/j.cell.2020.02.052 10.1126/sciimmunol.abc3582 10.1016/j.celrep.2020.108175 10.1038/s41591-020-0868-6 10.1126/sciadv.abc5801 10.3389/fmed.2020.580796 10.1038/ijos.2013.46 10.1242/dev.136010 10.1038/s41467-020-18512-7 10.7554/eLife.62810 10.1016/j.stem.2019.11.005 10.1016/j.stem.2018.10.015 10.1038/s41586-018-0394-6 10.1902/jop.1982.53.4.231 10.3389/fimmu.2018.02902 10.1038/mi.2015.136 10.1111/omi.12195 10.1038/s41590-018-0051-0 10.4049/jimmunol.1003126 10.1177/10454411000110040101 10.1016/j.cell.2020.04.035 10.1038/s41591-019-0468-5 10.1016/j.cell.2019.06.029 10.1016/S2666-5247(20)30144-0 10.1126/sciimmunol.abe8063 10.1111/j.1600-0714.1989.tb00758.x 10.1038/s41598-018-25311-0 10.3201/eid2606.200516 10.1056/NEJMc2016359 10.1016/S0002-9440(10)63964-8 10.1186/s12891-015-0773-1 10.1016/S0140-6736(08)60419-5 10.1016/S0003-9969(03)00014-1 10.1056/NEJMe2009758 10.1902/jop.1965.36.3.177 10.1902/jop.2009.080645 10.1902/jop.1967.38.6_part2.610 10.1186/s13059-017-1382-0 10.1038/s41592-019-0619-0 10.1093/infdis/jiaa273 10.1177/0022034510390811 10.1016/j.it.2017.08.005
Nature Medicine; Huang N, Pérez P et. al.

Mar 26th, 2021 - Despite signs of infection-including taste loss, dry mouth and mucosal lesions such as ulcerations, enanthema and macules-the involvement of the oral cavity in coronavirus disease 2019 (COVID-19) is poorly understood. To address this, we generated and analyzed two single-cell RNA sequencing datasets of the human minor salivary glands and gingiva (9 samples, 13,824 cells), identifying 50 cell cl...

Obesity pandemic during COVID-19 outbreak: Narrative review and future considerations.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923945
Clinical Nutrition (Edinburgh, Scotland); Cava E, Neri B et. al.

Mar 25th, 2021 - The high prevalence of obesity and obesity-related comorbidities has reached pandemic proportions, particularly in Western countries. Obesity increases the risk to develop several chronic noncommunicable disease, ultimately contributing to reduced survival. Recently, obesity has been recognized as major risk factor for coronavirus disease-19 (COVID-19)-related prognosis, contributing to worse o...

Risk factors for SARS-CoV-2 re-positivity in COVID-19 patients after discharge.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953440
International Immunopharmacology; Hong LX, Liu L et. al.

Mar 23rd, 2021 - Re-positivity of SARS-CoV-2 in discharged COVID-19 patients have been reported; however, early risk factors for SARS-CoV-2 re-positivity evaluation are limited. This is a prospective study, a total of 145 COVID-19 patients were treated and all discharged according to the guideline criteria by Mar 11th 2020. After discharge, clinical visits and viral RT-PCR tests by the second and fourth week fo...

Recombinant IFN Plus Antivirals May Boost COVID-19 Recovery Versus Traditional IFN
https://www.medscape.com/viewarticle/947889

Mar 22nd, 2021 - NEW YORK (Reuters Health) - In patients with moderate-severe COVID-19, recombinant super-compound interferon (rSIFN-co) plus baseline antivirals was associated with a shorter time to clinical improvement than the same regimen using traditional interferon-alpha in an exploratory trial in China. "Since no antiviral agents were confirmed to be effective for COVID-19 during our study period, there ...

Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV...
https://doi.org/10.1080/1744666X.2021.1905525
Expert Review of Clinical Immunology; Ameratunga R, Woon ST et. al.

Mar 22nd, 2021 - Introduction: Diagnostic tests play a critical role in the management of Sars-CoV-2, the virus responsible for COVID-19. There are two groups of tests, which are in widespread use to identify patients who have contracted the virus. The commonly used reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) test becomes negative once viral shedding ceases by approximately 2-3weeks. ...

Analytical performances of the point-of-care SIENNA™ COVID-19 Antigen Rapid Test for th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970753
International Journal of Infectious Diseases : IJID : Off... Mboumba Bouassa RS, Veyer D et. al.

Mar 22nd, 2021 - We herein assessed the analytical performances of the antigen-rapid diagnostic test (Ag-RDT) SIENNA™ COVID-19 Antigen Rapid Test Cassette (Nasopharyngeal Swab) (Salofa Oy, Salo, Finland), targeting the SARS-CoV-2 N nucleocapsid protein, for the diagnosis of COVID-19 in hospitalized patients with suspected SARS-CoV-2 infection, by reference to real-time RT-PCR (rRT-PCR). Nasopharyngeal swabs wer...

Clinical features and viral RNA shedding of imported and local cases with COVID-19 in W...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982230
Medicine He G, Wu J et. al.

Mar 17th, 2021 - Wenzhou had the highest number of confirmed novel coronavirus 2019 (COVID-19) cases outside the Hubei province. The aim of this study was to identify the difference in clinical features and viral RNA shedding between the imported and local COVID-19 cases in Wenzhou.All patients with confirmed COVID-19 admitted to Wenzhou Sixth People's Hospital, Wenzhou Central Hospital Medical Group, from Janu...

Clofazimine broadly inhibits coronaviruses including SARS-CoV-2.
https://doi.org/10.1038/s41586-021-03431-4
Nature Yuan S, Yin X et. al.

Mar 17th, 2021 - The COVID-19 pandemic is the third outbreak this century of a zoonotic disease caused by a coronavirus, following the emergence of severe acute respiratory syndrome (SARS) in 20031 and Middle East respiratory syndrome (MERS) in 20122. Treatment options for coronaviruses are limited. Here we show that clofazimine-an anti-leprosy drug with a favourable safety profile3-possesses inhibitory activit...

Reinfection Rates among Patients who Previously Tested Positive for COVID-19: a Retrosp...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989568
Clinical Infectious Diseases : an Official Publication Of... Sheehan MM, Reddy AJ et. al.

Mar 15th, 2021 - Protection afforded from prior disease among patients with coronavirus disease 2019 (COVID-19) infection is unknown. If infection provides substantial long-lasting immunity, it may be appropriate to reconsider vaccination distribution plans. This retrospective cohort study of one multi-hospital health system included 150,325 patients tested for COVID-19 infection via PCR from March 12, 2020 to ...

Antibody Cocktail Seems to Prevent Family Spread of Disease in COVID-19
https://www.medscape.com/viewarticle/947197

Mar 9th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. A one-time injection of the monoclonal antibody cocktail casirivimab with imdevimab (REGEN-COV), taken within 96 hours of a household member's diagnosis with SARS-CoV-2, prevented 100% of COVID-19 illness, 100% of high SARS-CoV-2 viral loads, and cut length of asymptomatic infection to 1 week. A...

Longitudinal assessment of anti-SARS-CoV-2 immune responses for six months based on the...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989218
The Journal of Infectious Diseases; Noh JY, Kwak JE et. al.

Mar 9th, 2021 - There is insufficient data on the longevity of immunity acquired following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We aimed to evaluate the duration of SARS-CoV-2-specific humoral and cellular immunity according to the clinical severity of coronavirus disease 2019 (COVID-19). The study population comprised asymptomatic (n=14), symptomatic/non-pneumonic (n=42), an...

2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874914
European Journal of Cancer (Oxford, England : 1990); Giesen N, Sprute R et. al.

Mar 6th, 2021 - The worldwide spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated infectious coronavirus disease (COVID-19) has posed a unique challenge to medical staff, patients and their families. Patients with cancer, particularly those with haematologic malignancies, have been identified to be at high risk to develop severe COVID-19. Since publication of our previ...